<DOC>
	<DOCNO>NCT00113490</DOCNO>
	<brief_summary>The primary objective study determine effect immune reactivity motavizumab ( MEDI-524 ) monthly intramuscular ( IM ) dose motavizumab ( MEDI-524 ) administer second season child .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Immunogenicity Motavizumab ( MEDI-524 ) After Dosing Second Season Children</brief_title>
	<detailed_description>This Phase 1/2 , randomize , double-blind study motavizumab ( MEDI-524 ) palivizumab administer child previously participate MI-CP104 . Children receive least 3 dos motavizumab MI-CP104 eligible enrollment . Subjects randomize 1:1 receive motavizumab palivizumab 15 mg/kg IM injection every 30 day total 4-5 injection 2004-05 RSV season subsequent season participant MI-CP104 . All subject evaluate prior 30 minute injection study drug 2 follow-up evaluation , one 30 day 90-120 day last dose .</detailed_description>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Previous participation MICP104 receive least 3 injection MEDI524 MICP104 The child must less equal 24 month age time entry study ( child must enter 24month birthday ) The child must able complete followup visit 34 month last dose ( total length participation 68 month ) Written informed consent obtain patient 's parent ( ) legal guardian Currently hospitalize Receiving chronic oxygen therapy mechanical ventilation time study entry ( include continuous positive airway pressure [ CPAP ] ) Evidence infection hepatitis A , B , C virus Known renal impairment , hepatic dysfunction , chronic seizure disorder , immunodeficiency HIV infection Suspected serious allergic immune mediate event prior receipt MEDI524 Acute illness progressive clinical disorder Active infection , include acute respiratory syncytial virus ( RSV ) infection time enrollment Previous reaction IGIV , blood product , foreign protein Have ever receive palivizumab Received within past 120 day currently receive immunoglobulin product ( RSVIGIV [ RespiGam ( R ) ] , IVIG ) , investigational agent ( except MEDI524 ) Currently participate investigational study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>motavizumab , palivizumab , synagis</keyword>
	<keyword>Rezield , MEDI-524</keyword>
</DOC>